Fungi

Rritual, Premium North American Brand in the Emerging Functional Mushroom Market Announces Dr. Mike Hart as President

Retrieved on: 
Tuesday, June 23, 2020

VANCOUVER, British Columbia, June 23, 2020 /PRNewswire-PRWeb/ -- Rritual , the premium brand in the emerging functional mushroom market, announced today that Dr. Mike Hart has been named as the President of North America's leading mushroom adaptogens company.

Key Points: 
  • VANCOUVER, British Columbia, June 23, 2020 /PRNewswire-PRWeb/ -- Rritual , the premium brand in the emerging functional mushroom market, announced today that Dr. Mike Hart has been named as the President of North America's leading mushroom adaptogens company.
  • Rritual, the rapidly growing North American leader in the emerging functional mushroom market is transforming the functional food industry with their Reishi, Chaga, Cordyceps, and Lion's Mane mushroom focused super food product portfolio which currently includes elixirs, mixes and shots combined with synergistic adaptogenic herbs.
  • Their data-backed, unique formulations for their premium, plant-based elixirs include key ingredients to help support cognitive function, stress relief, and boost immunity.
  • "Dr. Mike Hart is the perfect leader for Rritual," said David Kerbel, Chief Executive Officer.

Farmmi Subsidiary Receives Additional Repeat Order for Distribution in Israel

Retrieved on: 
Thursday, June 18, 2020

LISHUI, China, June 18, 2020 /PRNewswire/ -- Farmmi, Inc. ("Farmmi" or the "Company")(NASDAQ: FAMI), an agriculture products supplier in China, today announced its subsidiary Zhejiang Forest Food Co., Ltd., has received an additional repeat order for distribution of its Shiitake mushrooms and black fungus in Israel.

Key Points: 
  • LISHUI, China, June 18, 2020 /PRNewswire/ -- Farmmi, Inc. ("Farmmi" or the "Company")(NASDAQ: FAMI), an agriculture products supplier in China, today announced its subsidiary Zhejiang Forest Food Co., Ltd., has received an additional repeat order for distribution of its Shiitake mushrooms and black fungus in Israel.
  • Ms. Yefang Zhang, Farmmi's Chairwoman and CEO, commented, "While China has been the world's largest producer of high-quality Shiitake mushrooms, Israel has been a major consumer going back to ancient times.
  • In addition to the many potential benefits of including mushrooms (shveml in Yiddish) in a regular diet, mushrooms are kosher in their natural state once checked for bugs.
  • This latest order, our fifth from the same customer this year, reflects the healthy demand we are seeing and the overall momentum in our business in key markets worldwide."

MycoWorks Announces Expanded Executive Team

Retrieved on: 
Tuesday, June 16, 2020

SAN FRANCISCO, June 16, 2020 /PRNewswire/ --Biomaterials company MycoWorks today announced additions to their executive team: Chief Manufacturing Officer Doug Hardesty, Chief of Product Mike Todd, and Advisor John Diener.

Key Points: 
  • SAN FRANCISCO, June 16, 2020 /PRNewswire/ --Biomaterials company MycoWorks today announced additions to their executive team: Chief Manufacturing Officer Doug Hardesty, Chief of Product Mike Todd, and Advisor John Diener.
  • Doug brings to MycoWorks his tried-and-true "Vertical Start Up" playbook for rapid and predictable start-up of new manufacturing technologies, honed at Procter & Gamble.
  • Chief of Product Mike Todd is an experienced and accomplished supply chain executive with an extensive background in the Global Leather and Luxury Accessories markets.
  • "As we embark on scaling up the commercial production of Reishi, we are thrilled to add these experienced industry executives to the MycoWorks team," said MycoWorks CEO Matthew Scullin.

Mydecine Innovations Group Inc. Signs Partnership Agreement With Applied Pharmaceutical Innovation

Retrieved on: 
Monday, June 15, 2020

The agreement with API provides exceptional capacity for Mydecine and the ability to significantly speed their product development with leading experts in the pharmaceutical sciences and established drug development facilities.

Key Points: 
  • The agreement with API provides exceptional capacity for Mydecine and the ability to significantly speed their product development with leading experts in the pharmaceutical sciences and established drug development facilities.
  • Through the agreement, Mydecine has the ability to immediately commence fungal discovery investigations with varietal mushrooms and their extracts, including scheduled substances.
  • "Our partnership with the University of Alberta will unlock brand new avenues for the study of medical uses of mushrooms," Robert Roscow, CSO of Mydecine.
  • By developing a world class R&D program that discovers potential new lead compounds, synergistic effects, and increased therapeutic indications for mushroom-derived products, Mydecine will stand out in this bourgeoning sector.

Positive First Steps Show the Promise of Psychedelic Therapies

Retrieved on: 
Wednesday, June 10, 2020

For example, back in 2019, Denver voters approved some of the nation's first legal protections for psychedelic mushroom users, according to the Denver Post .

Key Points: 
  • For example, back in 2019, Denver voters approved some of the nation's first legal protections for psychedelic mushroom users, according to the Denver Post .
  • Just like with cannabis and CBD products, legalization efforts will be spread to both the national and local levels.
  • Such a wide scope of applications is also anticipated to further expand the target demographic of the market.
  • Psilocybin is a naturally occurring psychedelic compound produced by more than 200 species of mushrooms, collectively known as psilocybin mushrooms.

Positive First Steps Show the Promise of Psychedelic Therapies

Retrieved on: 
Wednesday, June 10, 2020

For example, back in 2019, Denver voters approved some of the nation's first legal protections for psychedelic mushroom users, according to the Denver Post .

Key Points: 
  • For example, back in 2019, Denver voters approved some of the nation's first legal protections for psychedelic mushroom users, according to the Denver Post .
  • Just like with cannabis and CBD products, legalization efforts will be spread to both the national and local levels.
  • Such a wide scope of applications is also anticipated to further expand the target demographic of the market.
  • Psilocybin is a naturally occurring psychedelic compound produced by more than 200 species of mushrooms, collectively known as psilocybin mushrooms.

COVID-19 Impact and Recovery Analysis- Chaga Mushroom-Based Products Market 2020-2024 | Health Benefits of Chaga Mushroom to Boost Growth | Technavio

Retrieved on: 
Monday, June 8, 2020

The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.

Key Points: 
  • The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.
  • Market estimates include pre- and post-COVID-19 impact on the Chaga Mushroom-Based Products Market Download free sample report
    The market is fragmented, and the degree of fragmentation will accelerate during the forecast period.
  • The health benefits of chaga mushroom has been instrumental in driving the growth of the market.
  • https://www.technavio.com/report/report/chaga-mushroom-based-products-ma...
    Chaga Mushroom-Based Products Market 2020-2024: Segmentation
    Chaga Mushroom-Based Products Market is segmented as below:

Hollister Biosciences Inc. Subsidiary AlphaMind Brands Inc. Plans to Launch Initial Medicinal Mushroom Based Product Line

Retrieved on: 
Thursday, June 4, 2020

VANCOUVER, BC, June 4, 2020 /PRNewswire/ -Hollister Biosciences Inc. (CSE: HOLL) (OTCPINK: HSTRF)(Frankfurt: HOB) (the "Company", "Hollister Cannabis Co." or "Hollister") a diversified cannabis branding company with products in over 220 dispensaries throughout California, is pleased to announce that the Company's 100% owned subsidiary, AlphaMind Brands Inc. ("AlphaMind") plans to launch medicinal mushroom based capsule and powder product lines.

Key Points: 
  • VANCOUVER, BC, June 4, 2020 /PRNewswire/ -Hollister Biosciences Inc. (CSE: HOLL) (OTCPINK: HSTRF)(Frankfurt: HOB) (the "Company", "Hollister Cannabis Co." or "Hollister") a diversified cannabis branding company with products in over 220 dispensaries throughout California, is pleased to announce that the Company's 100% owned subsidiary, AlphaMind Brands Inc. ("AlphaMind") plans to launch medicinal mushroom based capsule and powder product lines.
  • The initial product line will consist of a blended and bottled powder and capsule consisting of powdered cordyceps, lion's mane, oyster, reishi and shiitake medicinal mushroom varietals.
  • Raw materials for the product line have arrived at Alphamind's manufacturing partner, Kirkman and have been sent off for third party testing.
  • Alphamind Brands is a Canada and US based growth stage company, that is developing a portfolio of certified legal mushroom based natural health products.

Yeast Market Worth $6.1 Billion by 2025 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Tuesday, May 26, 2020

CHICAGO, May 26, 2020 /PRNewswire/ -- According to the new market research report "Yeast Marketby Type (Baker's Yeast, Brewer's Yeast, Wine Yeast, Probiotics Yeast), Form (Active, Instant, Fresh), Genus (Saccharomyces, Kluyveromyces), Application (Food, Feed), and Region - Global Forecast to 2025", published by MarketsandMarkets, the global Yeast Market size is projected to reach USD 6.1 billion by 2025.

Key Points: 
  • CHICAGO, May 26, 2020 /PRNewswire/ -- According to the new market research report "Yeast Marketby Type (Baker's Yeast, Brewer's Yeast, Wine Yeast, Probiotics Yeast), Form (Active, Instant, Fresh), Genus (Saccharomyces, Kluyveromyces), Application (Food, Feed), and Region - Global Forecast to 2025", published by MarketsandMarkets, the global Yeast Market size is projected to reach USD 6.1 billion by 2025.
  • According to MarketsandMarkets, the global yeast market size is estimated to be valued at USD 3.9 billion in 2020 and is projected to reach USD 6.1 billion by 2025, recording a CAGR of 9.6%.
  • Based on form, the yeast market is segmented into active, instant, and fresh.
  • Specialty Yeast Marketby Type (Yeast Extracts, Yeast Autolysates, Yeast Beta-glucan, and Other Yeast Derivatives), Species (Saccharomyces Cerevisiae, Pichia Pastoris, Kluyveromyces), Application, and Region Global Forecast to 2025

Yeast Market Worth $6.1 Billion by 2025 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Tuesday, May 26, 2020

CHICAGO, May 26, 2020 /PRNewswire/ -- According to the new market research report "Yeast Marketby Type (Baker's Yeast, Brewer's Yeast, Wine Yeast, Probiotics Yeast), Form (Active, Instant, Fresh), Genus (Saccharomyces, Kluyveromyces), Application (Food, Feed), and Region - Global Forecast to 2025", published by MarketsandMarkets, the global Yeast Market size is projected to reach USD 6.1 billion by 2025.

Key Points: 
  • CHICAGO, May 26, 2020 /PRNewswire/ -- According to the new market research report "Yeast Marketby Type (Baker's Yeast, Brewer's Yeast, Wine Yeast, Probiotics Yeast), Form (Active, Instant, Fresh), Genus (Saccharomyces, Kluyveromyces), Application (Food, Feed), and Region - Global Forecast to 2025", published by MarketsandMarkets, the global Yeast Market size is projected to reach USD 6.1 billion by 2025.
  • According to MarketsandMarkets, the global yeast market size is estimated to be valued at USD 3.9 billion in 2020 and is projected to reach USD 6.1 billion by 2025, recording a CAGR of 9.6%.
  • Based on form, the yeast market is segmented into active, instant, and fresh.
  • Specialty Yeast Marketby Type (Yeast Extracts, Yeast Autolysates, Yeast Beta-glucan, and Other Yeast Derivatives), Species (Saccharomyces Cerevisiae, Pichia Pastoris, Kluyveromyces), Application, and Region Global Forecast to 2025